Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01849861
Other study ID # idosos01
Secondary ID
Status Recruiting
Phase Phase 4
First received April 23, 2013
Last updated May 10, 2013
Start date September 2011
Est. completion date September 2014

Study information

Verified date May 2013
Source Universidade Federal do Rio de Janeiro
Contact Dhiãnah SO Chachamovitz
Phone +552126203063
Email dhianahsantini@gmail.com
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

The purpose of this study is to correlate in an elderly population (≥ 65 years), the different levels of serum TSH, with cardiopulmonary capacity, quality of life, depressive symptoms and cognition. And assess whether the increased serum TSH to the upper half of the normal range, through the use of antithyroid drugs, is associated with improvements in these parameters.


Description:

Specific Objectives:

Describe the cardiopulmonary capacity in elderly people with 65 years old or more, in different quartiles of normal range for serum TSH.

Assess the quality of life, mini mental health status and depression scale in seniors aged 65 or older, in different quartiles of normal range for serum TSH.

Quantify the possible effects related to the use of antithyroid drugs in cardiopulmonary capacity, quality of life, mini mental health status and depression scale in elderly people aged 65 or more, with the initial serum TSH at the lower limit of the normal range (1.0 milli-International unit/ml) (mIU/ml).

Justification:

Despite evidence that in the elderly population the mean serum TSH tends to be higher as compared to younger adults, there isn't a curve of normal range of TSH for this specific population (more shifted to the right, which would increase the number of diagnoses for subclinical hyperthyroidism).

Thus, elderly individuals, even when classified as euthyroidism, but presenting TSH in the normal lower range, may present at a greater risk of cardiovascular disease and therefore, may have indication for treatment.

These findings motivate and justify this study design, which may have great clinical relevance in the scientific community for its originality, and important clinical applicability.

Materials and Methods:

If the patient agrees to participate, an appointment will be scheduled at HUCFF that will be made: anamnesis, review of medical records, clinical examination and signing the Informed Consent Form (ICF).

Secondly, they will be guided and directed to: laboratory analysis for serum dosage of TSH and free thyroxine (FT4), cardiopulmonary exercise testing and application of the questionnaires of quality of life, mini mental health status and depression.

The study comprised of two parts:

Phase 1: Sectional:

- Analysis of variables.

- Sample as a whole and according to the quartiles of the reference range for serum TSH, with comparisons between groups.

- 1st Quartile: TSH: 0.4 to 1.0 mIU / ml.

- 2nd Quartile: TSH: 1.0 to 2.0 mIU / ml.

- 3rd Quartile: TSH: 2.0 to 3.0 mIU / ml.

- 4th Quartile: TSH: 3.0 to 4.0 mIU / ml Phase 2: Clinical uncontrolled. Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).

After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.

Variables considered in this study:

- TSH and FT4

- Questionnaire of Quality of life for older adults (WHOQOL-OLD)

- Mini-Mental State Examination

- Geriatric Depression Scale

- Cardiopulmonary exercise testing - cardiopulmonary capacity Variables to be analyzed at rest, peak of the exercise and recovery: Heart rate, systolic blood pressure and diastolic blood pressure.

Variables to be assessed at peak effort: pulmonary ventilation, oxygen consumption, carbon dioxide production, ventilatory equivalent for oxygen and carbon dioxide, respiratory quotient, oxygen pulse, fraction of expired oxygen and carbon dioxide.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 2014
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Age = 65 years.

- Healthy Men and women

- Registration at the University Hospital Clementino Fraga Filho (HUCFF).

Exclusion Criteria:

- Hypothalamic-pituitary disease

- Congestive cardiac insufficiency, chronic renal failure, acute renal failure, stroke, chronic obstructive pulmonary disease, asthma, cancer and / or cirrhosis.

- Diseases of the aorta, peripheral vascular disease, coronary artery disease (including angina, history of prior myocardial infarction or angina, or history of cardiac catheterization and angioplasty).

- Use of corticosteroids, amiodarone or dopamine, as well as any drug that interferes with the levels of thyroid hormones and / or thyroid function.

- Use of drugs that interfere with autonomic adaptation mechanism, such as beta-blockers, prolopa and calcium channel blockers. Hypertensive patients without use of such drugs may be included.

- Patients bedridden, wheelchair or with physical limitations (joint and muscle) to prevent the standing position for at least 20 minutes and the realization of the cardiopulmonary exercise test.

- Obesity with a body mass index equal or greater than 35 kg/m2.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
Methimazole
Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal). After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables. Variables considered in this study: TSH and FT4 Questionnaire of Quality of life for older adults (WHOQOL-OLD) Mini-Mental State Examination Geriatric Depression Scale Cardiopulmonary exercise testing - cardiopulmonary capacity

Locations

Country Name City State
Brazil Universidade Federal do Rio de Janeiro Rio de Janeiro

Sponsors (2)

Lead Sponsor Collaborator
Universidade Federal do Rio de Janeiro Conselho Nacional de Desenvolvimento Científico e Tecnológico

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlate in a population of more than 65 years old, the different levels of serum TSH, with cardiopulmonary capacity and these effects from baseline after treatment with antithyroid drugs Describe the cardiopulmonary capacity in elderly health population of 65 years old or more, in different quartiles of normal range for serum TSH.
Assess the outcome in the cardiopulmonary capacity in seniors aged 65 years old or more, in different quartiles of normal range for serum TSH.
Quantify the possible changes from baseline related to the use of antithyroid drugs in cardiopulmonary capacity in patients aged 65 or more, with the initial serum TSH at the lower limit of the normal range (1.0 mIU/ml)to values of TSH more than 2.0mUI/ml for six months.
six months Yes
Secondary Assess the quality of life in seniors aged 65 years old or older, in different quartiles of normal range for serum TSH and these changes from baseline after use of methimazole Describe the quality of life in elderly health population of 65 years old or more, in different quartiles of normal range for serum TSH.
Assess the outcome in quality of life in seniors aged 65 olde or more, in different quartiles of normal range for serum TSH
Quantify the possible changes from baseline related to the use of antithyroid drugs in quality of life in patients aged 65 or more, with the initial serum TSH at the lower limit of the normal range (1.0 mIU/ml)to values of TSH more than 2.0mUI/ml for six months..
six months Yes
Secondary Assess the mini mental health status in seniors aged 65 years old or older, in different quartiles of normal range for serum TSH and these changes from baseline after use of methimazole Describe the mini mental health status in elderly health population of 65 years old or more, in different quartiles of normal range for serum TSH.
Assess the outcome in mini mental health status in seniors aged 65 olde or more, in different quartiles of normal range for serum TSH.
Quantify the possible changes from baseline related to the use of antithyroid drugs in mini mental health status in patients aged 65 or more, with the initial serum TSH at the lower limit of the normal range (1.0 mIU/ml)to values of TSH more than 2.0mUI/ml for six months.
six months Yes
Secondary Assess the depression scale in seniors aged 65 years old or older, in different quartiles of normal range for serum TSH and these changes from baseline after use of methimazole Describe the depression scale in elderly health population of 65 years old or more, in different quartiles of normal range for serum TSH.
Assess the outcome in depression scale in seniors aged 65 olde or more, in different quartiles of normal range for serum TSH.
Quantify the possible changes from baseline related to the use of antithyroid drugs in the depression scale in patients aged 65 years old or more, with the initial serum TSH at the lower limit of the normal range (1.0 mIU/ml)to values of TSH more than 2.0mUI/ml for six months..
six months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1